Hepatitis C virus–HIV-coinfected patients and liver transplantation

Current Opinion in Organ Transplantation

Volumn 20, Issue 3, 2015, Pages 276-285

  Kardashian, Ani A ^a   Price, Jennifer C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Direct acting antivirals; Hepatitis C virus; HIV; Liver transplantation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; DASABUVIR; DIRECT ACTING ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

COINFECTION; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; COMPLICATION; GRAFT SURVIVAL; MIXED INFECTION; TREATMENT OUTCOME;

COINFECTION; GRAFT SURVIVAL; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84969428143     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000199     Document Type: Review

References (74)

1. Feinberg MB. Changing the natural history of HIV disease. Lancet 1996; 348:239–246.
2. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl 1):S5–S14.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
4. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in & people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241–248. This study shows that liver disease is a leading cause of morbidity and mortality in patients with HIV infection.
5. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188:1412–1420.
6. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8:355–365.
7. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7:2816–2820.
8. Bonnard P, Lescure FX, Amiel C, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007; 14:806–811.
9. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008; 148:728–736.
10. Soto B, Sánchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1–5.
11. Girón-González JA, Brun F, Terrón A, et al. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study. Antivir Ther 2007; 12:899–907.
12. Merchante N, Girón-González JA, González-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49–57.
13. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41:779–789.
14. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593–601.
15. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921–1926.
16. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57:249–257.
17. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527–537.
18. Merchante N, Merino E, López-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013; 56:143–150.
19. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285–2293.
20. Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10:1268–1275.
21. Tateo M, Roque-Afonso AM, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23:1069–1076.
22. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889–896.
23. Duclos-Vallée J-C, Féray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407–417.
24. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012; 12:1866–1876.
25. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transplant 2012; 18:716–726.
26. De Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6:2983–2993.
27. Antonini TM, Sebagh M, Roque-Afonso AM, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011; 11:1686–1695.
28. Narang TK, Ahrens W, Russo MW. Postliver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transplant 2010; 16:1228–1235.
29. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10:87–92.
30. Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant 2010; 15:301–309.
31. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250–256.
32. Moreno A, Cervera C, Fortún J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transplant 2012; 18:70–81.
33. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007; 84:563–571.
34. Fox AN, Vagefi PA, Stock PG. Liver transplantation in HIV patients. Semin Liver Dis 2012; 32:177–185.
35. Lai JC, O’Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transplant 2012; 18:532–538.
36. Price JC, Terrault NA. CON sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective. Liver Int 2015; 35:7–8.
37. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent && recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2014; 148:100–107. This study demonstrates that pre-transplant HCV treatment with DAAs can prevent post-transplant HCV recurrence, particularly if HCV RNA is not detected for 1 month prior to transplant.
38. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of && compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148:108–117. This study was one of the first to show that an all-oral, non-IFN based DAA regimen is both safe and effective in treating recurrent hepatitis C after liver transplantation.
39. Reddy K, Everson G, Flamm S, et al. Ledipasvir-sofosbuvir with ribavirin for the & treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. [Abstract 8]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7–11 November 2014; Boston, Massachusetts, USA. Preliminary data from this study showed record high SVR12 in a very difficult-to-treat population of patients with recurrent HCV with CPT A, B, and C cirrhosis after liver transplantation.
40. Kwo PY, Mantry PS, Coakley E, et al. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. N Engl J Med 2014.
41. Brown R, Reddy K, O’Leary J, et al. Safety and efficacy of new DAA-based therapy for hepatitis C posttransplant: interval results from the HCV-TARGET longitudinal, observational study. [Abstract LB-4]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7–11 November 2014; Boston, Massachusetts, USA.
42. Pungpapong S, Werner K, Aqel B, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation. [Abstract 9]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7–11 November 2014; Boston, Massachusetts, USA.
43. Campos-Varela I, Straley S, Agudelo EZ, et al. Sofosbuvir, Simeprevir plus ribavirin for treatment of HCV recurrence in HIV-HCV coinfected liver transplant recipients. Liver Transplant 2015; 21:272–274.
44. Borentain P, Colson P, Dhiver C, et al. Successful treatment with sofosbuvir of & fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient. Antivir Ther 2014. doi: 10.3851/IMP2841. This is the first report of successful treatment of post-transplant recurrent HCV infection in an HIV/HCV coinfected patient with an interferon-free regimen. 45. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis && C in patients with HIV coinfection. JAMA 2014; 312:353–361. This study showed high SVR rates in HIV/HCV-coinfected patients with an all-oral DAA regimen, underscoring the notion that HIV is no longer a risk factor for poorer HCV treatment response, as it was with interferon-based regimens.
45. Graham CS, Wells A, Liu T, et al. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/ hepatitis C virus co-infection. AIDS 2006; 20:345–351.
46. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483–1493.
47. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889–1898.
48. Bourlière M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/ sofosbuvir with or without ribavirin [Abstract 82]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7–11 November 2014; Boston, Massachusetts.
49. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594–1603.
50. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604–1614.
51. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359–365.
52. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir && with or without ribavirin for HCV. N Engl J Med 2014; 370:1983–1992. This is the largest study to date of all-oral DAA treatment for recurrent hepatitis C after liver transplantation.
53. Wyles DL, Sulkowski MS, Eron JJ, et al. TURQUOISE-I: 94% SVR12 in HCV/ HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. [Abstract 1939]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 7–11 November 2014a; Boston, Massachusetts, USA.
54. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973–1982.
55. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756–1765.
56. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878–1887.
57. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867–1877.
58. Rockstroh J, Puoti M, Rodriguez-Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT1–4 infection: the PHOTON-1 and -2 trials. [Abstract 195]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 7–11 November 2014; Boston, Massachusetts, USA.
59. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993–2001.
60. Esmat GE, Shiha G, Omar RF et al. Sofosbuvir plus ribavirin in the treatment of egyptian patients with chronic genotype 4 HCV infection. [Abstract 959] In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 7–11 November 2014; Boston, Massachusetts, USA.
61. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. [Abstract 240]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 7–11 November 2014; Boston, Massachusetts, USA.
62. Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. [Abstract 1928]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 7–11 November 2014; Boston, MA.
63. Osinusi A, Townsend K, Nelson A, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: results from The NIAID ERADICATE trial [Abstract 84]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 7 November2014; Boston, Massachusetts, USA.
64. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1087–1097.
65. TM (sofosbuvir) tablets prescribing information. Gilead Sciences, Inc., Foster City, CA 2013, USA. [Accessed 10 January 2015].
66. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and && treating hepatitis C. Unique Patient Populations: Patients with HIV/HCV Coinfection. http://hcvguidelines.org/full-report/unique-patient-populations-patients-hivhcv-coinfection. [Accessed 27 January 2015]. These guidelines provide the most up-to-date recommendations for treating hepatitis C in HIV-coinfected individuals.
67. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines & for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. [Accessed 21 January 2015]. These guidelines provide an excellent review of pharmacokinetic interactions between HIV antiretroviral drugs and direct acting antiviral agents against HCV, as well as current recommendations for concomitant use of these drugs.
68. El-Sadr WM, Lundgren JD, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4þ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283–2296.
69. Thorpe J, Saeed S, Moodie EEM, Klein MB. Canadian Co-infection Cohort Study. (CTN222). Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 2011; 25:967–975.
70. Frassetto L, Thai T, Aggarwal AM, et al. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIVþ subjects. Drug Metab Pharmacokinet 2003; 18:114–120.
71. Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80:13–17.
72. Vogel M, Voigt E, Michaelis H-C, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transplant 2004; 10:939–944.
73. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9:1946–1952.
74. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006; 26:273–284.